Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Oct 18, 2022 6:03pm
166 Views
Post# 35032551

RE:Pfizer response to questions on M&A -> add value to company

RE:Pfizer response to questions on M&A -> add value to company"According to the 2021 Corporate Reputation survey from PatientView, which asked 520 cancer patient groups which was their most favored and reputable pharma company last year. Pfizer has become the most reputable pharma company for cancer patient groups, knocking Roche out of the top spot.

Roche topped the tables in 2020, but last year it was Pfizer who came in at No. 1 across the two groups of drugmakers PatientView uses to determine which is the most reputable.

Pfizer isn’t the biggest oncology player; that title goes to Roche, and it's no surprise that it’s a regular winner of these rep lists."

https://www.fiercepharma.com/marketing/pfizer-topples-oncology-giant-roche-cancer-patient-groups-reputation-list
 
 
<< Previous
Bullboard Posts
Next >>